Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Gold Prices Slip as Strong Dollar and Rising Oil Weigh on Market Sentiment 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
US Stock Futures Slip as Trump Rejects Iran Peace Proposal Amid Rising Middle East Tensions 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
Gold Prices Hold Firm as Traders Watch U.S.-Iran Ceasefire and Trump-Xi Talks 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
